GlassScriptPhysician profile
Jay L Koyner
NPI 1275656340
$112,912.85
in general payments reported to CMS, 2019-2025
10 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,310 · 2021: $16K · 2022: $14K · 2023: $15K · 2024: $13K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Education: $8,685 · Travel and Lodging: $2,927 · Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,055.50 |
| Education | $8,685.00 |
| Travel and Lodging | $2,926.89 |
| Food and Beverage | $1,877.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $51,141.32 | 2019-2025 | Renal - Acute |
| Alexion Pharmaceuticals, INC. | $22,267.75 | 2023-2025 | Ultomiris |
| Vantive US Healthcare LLC | $14,064.13 | 2025 | Renal - Acute, Renal - Pd |
| Biomerieux INC | $13,200.00 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $6,225.00 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $3,964.14 | 2025 | Nxstage System One |
| Nxstage Medical, INC. | $1,775.00 | 2021-2022 | |
| Exthera Medical Corporation | $144.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $130.83 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Koyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.